B-cell activation markers and cancer risk in people with HIV: An integrative case-control and Mendelian randomization analysis

Clicks: 8
ID: 339173
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #77 of 78 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Early and continuous antiretroviral therapy (ART) reduces cancer risk in people with HIV (PWH), yet residual risk potentially driven by persistent B-cell activation remains. We used observational and genetic triangulation to evaluate whether baseline B-cell biomarkers are associated with subsequent cancer risk. We conducted: (i) a nested case-control study within the INSIGHT trials (158 cases and 313 matched controls) assessing B-cell biomarkers (sCD23, sCD27, sCD30, CXCL13) in PWH; and (ii) two-sample Mendelian randomization (MR) to evaluate likely causal relationships between these proteins and 23 cancer types using general-population genome-wide association studies. Median time from study entry to cancer diagnosis was 2.9 years. In PWH, CXCL13 was associated with overall cancer risk (highest tertile vs. lowest tertile OR 2.36, 95% CI 1.24-4.5), driven by infection-related cancers (N = 82; OR 4.81, 1.76-13.1) and lymphoma (N = 36; OR 9.92, 1.58-62.2). The CXCL13 association remained robust among virally suppressed participants (P = 0.018). sCD30 was also associated with infection-related cancers (OR 2.77, 1.09-7.03). sCD23 showed a linear association with infection-related cancer (OR per SD 1.42, 1.01-2.00), though tertile-based analyses were non-significant. In the general population, MR meta-analyses showed null associations for these biomarkers across 23 cancer types (P > 0.05). Our study links B-cell markers with cancer risk in PWH, identifying CXCL13 as a marker of infection-related cancer risk despite effective ART, highlighting a "residual inflammatory gap" for modern risk stratification. The lack of causal MR signals suggests these proteins are markers of HIV-associated immune activation rather than universal etiological factors for cancer.
Reference Key
openalex_W7225431079 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ricardo Cortez Cardoso Penha, Ramya Ramaswami, Jacqueline A. Nordwall, Andrew Phillips, Marie Helleberg, Anuradha Ganesan, Jennifer Hoy, Sophie Grabar, Duncan Charles Gilbert, Angela M. Crook, Ellen Kitchell, Jakob J Malin, Amit C. Achhra, Nagalingeswaran Kumarasamy, Cavan S Reilly, Maja Milojevic, Jens Dilling Lundgren
Are you one of these authors? Claim your profile
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag119
URL
https://doi.org/10.1093/jncics/pkag119
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.